Virax Biolabs Group Ltd (VRAX) News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs to Present at 19th World Immune Regulation Meeting

Virax Biolabs to Present at 19th World Immune Regulation Meeting PR Newswire LONDON, March 5, 2025 LONDON...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

Virax Biolabs' CEO James Foster Issues Letter to Shareholders PR Newswire LONDON, Dec. 17, 2024 LONDON, Dec...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]